Clostridium perfringens Delta toxin targets CD9 to drive NEC and brain injury

Necrotizing enterocolitis (NEC) is the most devastating gastrointestinal emergency in preterm infants, frequently causing mortality and long-term neurodevelopmental impairment1,2. Although the gut microbiota has been implicated in NEC pathogenesis3-5, the microbial factors driving NEC and the following brain pathology remain unclear. Here we identify Clostridium perfringens pathobionts containing Delta toxin in the gut microbiome of individuals with severe and fatal NEC. Clinically, infected infants show worse outcomes, including aberrant systemic inflammation, severe neurological damage and coagulopathy. We establish a mouse model in which Delta-toxin-positive C. perfringens infection, or Delta toxin exposure alone, recapitulates clinical features of NEC, including intestinal necrosis and acute cerebral injury. Mechanistically, Delta toxin preferentially targets macrophages, potently activating inflammasome signalling and pyroptosis, triggering a rapid inflammatory cascade that compromises blood-brain barrier integrity and drives neuroinflammation. Through a genome-wide CRISPR screen, we identify the tetraspanin CD9 as the host receptor for Delta toxin. Using systemic, myeloid-specific and intestinal-epithelial-specific Cd9-knockout mice, we show that systemic and myeloid Cd9 ablation protects mice against toxin-induced lethality, blood-brain barrier dysfunction and multiorgan injury, whereas epithelial Cd9 deletion shows partial protection, implicating macrophage targeting as a primary driver of C. perfringens CD9-dependent pathogenesis. Furthermore, a neutralizing anti-Delta toxin monoclonal antibody confers protection against disease progression. These findings suggest that a subset of NEC is a specific-toxin-mediated disorder and validate the Delta toxin-CD9 axis as a therapeutic target for this subset.

Shimeng Zhang, Xiaoqing Gong, Songhai Tian, Yang Yang, Xinru Tong, Kuanwei Sheng, Yifan Zhang, Sho Amatsu, Xi Zhang, Daiyue Yu, Hongtao Zhao, Lin Ruan, Honglu Sun, Kai Wu, Min Dong, Xiaozhe Xiong

Leverage3 / 5

A method or resource many groups across the field will adopt within a year.

10% of this desk’s rubric

Magnitude3 / 5

Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.

20% of this desk’s rubric

Evidence3 / 5

Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.

32% of this desk’s rubric

Novelty3 / 5

A genuinely new approach to an open problem.

8% of this desk’s rubric

Trajectory2 / 5

Some room to improve with obvious engineering.

5% of this desk’s rubric

Stakes3 / 5

Meaningful benefit to many people within a few years.

25% of this desk’s rubric

• Citations0 (reference 20, via openalex, Oct 30, 2026, 05:48 UTC)

• Reviewed by heuristic-v10 on Oct 30, 2026, 06:17 UTC. Paper type: method.
• Categories: Journal Article
• BRIEF, No.7 in the Biology edition of October 30, 2026.